Alan Schatzberg

Alan Schatzberg's AcademicInfluence.com Rankings

Alan Schatzberg

Biology

#2738

World Rank

#4311

Historical Rank

#1193

USA Rank

biology Degrees

Download Badge

Biology

Why Is Alan Schatzberg Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Alan F. Schatzberg is an American psychiatrist. He was the 136th president of the American Psychiatric Association . Since 1991, he has been the Kenneth T. Norris Jr . Professor of Psychiatry and Behavioral Sciences at Stanford University School of Medicine, and he was chair of the department from 1991 to 2010. He has received multiple national and international awards for his work as an investigator in the biology and treatment of depression. He is also the co-editor-in-chief of the Journal of Psychiatric Research, along with Florian Holsboer. He received an honorary doctorate from the Medical University of Vienna in 2011.

(See a Problem?)

Alan Schatzberg's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Dissociable Intrinsic Connectivity Networks for Salience Processing and Executive Control (2007) (5884)
Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs (2013) (2011)
Resting-State Functional Connectivity in Major Depression: Abnormally Increased Contributions from Subgenual Cingulate Cortex and Thalamus (2007) (2011)
Major depressive disorder (2016) (1913)
Resting-state connectivity biomarkers define neurophysiological subtypes of depression (2016) (1344)
Genome-wide association study identifies 30 Loci Associated with Bipolar Disorder (2017) (998)
A Placebo-Controlled, Double-blind, Randomized Trial of an Extract of Ginkgo Biloba for Dementia (1997) (979)
Large-scale genome-wide association analysis of bipolar disorder identifies a new susceptibility locus near ODZ4 (2011) (929)
Differential responses to psychotherapy versus pharmacotherapy in patients with chronic forms of major depression and childhood trauma (2003) (740)
On the interactions of the hypothalamic-pituitary-adrenal (HPA) axis and sleep: normal HPA axis activity and circadian rhythm, exemplary sleep disorders. (2005) (728)
Psychiatric genome-wide association study analyses implicate neuronal, immune and histone pathways (2015) (676)
Gender differences in treatment response to sertraline versus imipramine in chronic depression. (2000) (634)
Using chronic pain to predict depressive morbidity in the general population. (2003) (597)
Report by the ACNP Task Force on Response and Remission in Major Depressive Disorder (2006) (593)
Disrupted amygdalar subregion functional connectivity and evidence of a compensatory network in generalized anxiety disorder. (2009) (592)
A placebo-controlled, double-blind, randomized trial of an extract of Ginkgo biloba for dementia. North American EGb Study Group. (1997) (577)
Genomic Dissection of Bipolar Disorder and Schizophrenia, Including 28 Subphenotypes (2017) (517)
Social functioning in depression: a review. (2000) (505)
Failure of anterior cingulate activation and connectivity with the amygdala during implicit regulation of emotional processing in generalized anxiety disorder. (2010) (495)
Circadian patterns of gene expression in the human brain and disruption in major depressive disorder (2013) (464)
Effect of Hypericum perforatum (St John's wort) in major depressive disorder: a randomized controlled trial. (2002) (448)
Neuroendocrine aspects of hypercortisolism in major depression (2003) (436)
Prevalence of anxiety disorders and their comorbidity with mood and addictive disorders (1998) (419)
Gender differences in chronic major and double depression. (2000) (417)
HPA Axis in Major Depression: Cortisol, Clinical Symptomatology, and Genetic Variation Predict Cognition (2016) (405)
A Consensus Statement on the Use of Ketamine in the Treatment of Mood Disorders (2017) (356)
The treatment of chronic depression, part 3: psychosocial functioning before and after treatment with sertraline or imipramine. (1998) (328)
Altered expression of glutamate signaling, growth factor and glia genes in the locus coeruleus of patients with major depression (2010) (311)
Genome-wide association and meta-analysis of bipolar disorder in individuals of European ancestry (2009) (304)
Psychotic (delusional) major depression: should it be included as a distinct syndrome in DSM-IV? (1992) (299)
An open label trial of C-1073 (mifepristone) for psychotic major depression* (2002) (295)
Corticosteroids and cognition. (2001) (292)
Common abnormalities and disorder-specific compensation during implicit regulation of emotional processing in generalized anxiety and major depressive disorders. (2011) (282)
Mitochondrial involvement in psychiatric disorders (2008) (278)
Effects of the serotonin transporter gene promoter polymorphism on mirtazapine and paroxetine efficacy and adverse events in geriatric major depression. (2004) (275)
Attenuation of Antidepressant Effects of Ketamine by Opioid Receptor Antagonism. (2018) (268)
Pharmacogenetics of antidepressant medication intolerance. (2003) (266)
Rapid Reversal of Psychotic Depression Using Mifepristone (2001) (266)
Manual of clinical psychopharmacology (1991) (251)
Glucocorticoid and mineralocorticoid receptor mRNA expression in squirrel monkey brain. (2000) (249)
Prevalence of depressive episodes with psychotic features in the general population. (2002) (244)
Social phobia and depression: prevalence and comorbidity. (2010) (233)
A corticosteroid/dopamine hypothesis for psychotic depression and related states. (1985) (231)
Regional analysis of hippocampal activation during memory encoding and retrieval: fMRI study (2003) (224)
Does psychosocial functioning improve independent of depressive symptoms? a comparison of nefazodone, psychotherapy, and their combination (2002) (214)
Neuropsychological deficits in psychotic versus nonpsychotic major depression and no mental illness. (2000) (210)
Joint Analysis of Psychiatric Disorders Increases Accuracy of Risk Prediction for Schizophrenia, Bipolar Disorder, and Major Depressive Disorder (2015) (206)
Toward a biochemical classification of depressive disorders. I. Differences in urinary excretion of MHPG and other catecholamine metabolites in clinically defined subtypes of depressions. (1978) (205)
24-Hour monitoring of cortisol and corticotropin secretion in psychotic and nonpsychotic major depression. (2000) (204)
Double-Blind, Placebo-Controlled, Dose-Ranging Trial of Intravenous Ketamine as Adjunctive Therapy in Treatment-Resistant Depression (TRD) (2018) (203)
Cognitive-behavioral group therapy for social phobia in female adolescents: results of a pilot study. (2000) (202)
Cortisol Circadian Rhythm Alterations in Psychotic Major Depression (2006) (202)
Intranasal oxytocin administration attenuates the ACTH stress response in monkeys (2005) (201)
Mitochondrial Variants in Schizophrenia, Bipolar Disorder, and Major Depressive Disorder (2009) (201)
Age of onset in chronic major depression: relation to demographic and clinical variables, family history, and treatment response. (1999) (199)
Clinical and Biological Effects of Mifepristone Treatment for Psychotic Depression (2006) (197)
Maintenance phase efficacy of sertraline for chronic depression: a randomized controlled trial. (1998) (192)
Heroin use as an attempt to cope: clinical observations. (1974) (191)
Stanford accelerated intelligent neuromodulation therapy for treatment-resistant depression (SAINT-TRD) (2019) (186)
Maternal mediation, stress inoculation, and the development of neuroendocrine stress resistance in primates. (2006) (185)
Duloxetine 60 mg once-daily in the treatment of painful physical symptoms in patients with major depressive disorder. (2005) (180)
Double-blind, randomized comparison of mirtazapine and paroxetine in elderly depressed patients. (2002) (180)
Cortisol activity and cognitive changes in psychotic major depression. (2001) (176)
Childhood trauma predicts antidepressant response in adults with major depression: data from the randomized international study to predict optimized treatment for depression (2016) (175)
Serotonin reuptake inhibitor discontinuation syndrome: a hypothetical definition. Discontinuation Consensus panel. (1997) (174)
Impact of publicity concerning pediatric suicidality data on physician practice patterns in the United States. (2007) (173)
Which antidepressants have demonstrated superior efficacy? A review of the evidence (2007) (160)
Prospective investigation of stress inoculation in young monkeys. (2004) (160)
International Study to Predict Optimized Treatment for Depression (iSPOT-D), a randomized clinical trial: rationale and protocol (2011) (160)
Preliminary evidence that plasma oxytocin levels are elevated in major depression (2010) (157)
Chronic pain and major depressive disorder in the general population. (2010) (155)
Toward a biochemical classification of depressive disorders (1981) (154)
Serotonin transporter polymorphism, memory and hippocampal volume in the elderly: association and interaction with cortisol (2007) (153)
The American Psychiatric Press Textbook of Psychopharmacology (1995) (146)
The American Psychiatric Publishing Textbook of Psychopharmacology (2009) (145)
The dexamethasone suppression test: identification of subtypes of depression. (1983) (143)
Durability of clinical benefit with transcranial magnetic stimulation (TMS) in the treatment of pharmacoresistant major depression: assessment of relapse during a 6-month, multisite, open-label study (2010) (143)
Circadian dysregulation of clock genes: clues to rapid treatments in major depressive disorder (2014) (140)
A double-blind, placebo-controlled study of venlafaxine and fluoxetine in geriatric outpatients with major depression. (2006) (139)
Double-blind switch study of imipramine or sertraline treatment of antidepressant-resistant chronic depression. (2002) (138)
Developmental Cascades Linking Stress Inoculation, Arousal Regulation, and Resilience (2009) (137)
Chronic depression: medication (nefazodone) or psychotherapy (CBASP) is effective when the other is not. (2005) (135)
Animal models of early life stress: Implications for understanding resilience. (2010) (134)
Salivary cortisol levels in socially phobic adolescent girls (1999) (131)
Randomized clinical trial of the efficacy of bupropion combined with nicotine patch in the treatment of adolescent smokers. (2004) (130)
Early life stress and inherited variation in monkey hippocampal volumes. (2001) (126)
New indications for antidepressants. (2000) (126)
Stress-Level Cortisol Treatment Impairs Inhibitory Control of Behavior in Monkeys (2000) (126)
The Efficacy of Antidepressants in the Treatment of Late-Life Depression (2005) (125)
Clozapine in the treatment of refractory psychotic mania. (2000) (123)
Post-mortem molecular profiling of three psychiatric disorders (2016) (122)
Depression Subtypes in Predicting Antidepressant Response: A Report From the iSPOT-D Trial. (2015) (122)
Benzodiazepines in Depressive Disorders (1978) (121)
Neurobiological Signatures of Anxiety and Depression in Resting-State Functional Magnetic Resonance Imaging (2015) (120)
The Neuropsychological Profile of Psychotic Major Depression and its Relation to Cortisol (2006) (119)
Gender differences in presentation of chronic major depression. (1995) (118)
The international Study to Predict Optimized Treatment in Depression (iSPOT-D): outcomes from the acute phase of antidepressant treatment. (2015) (112)
National Depressive and Manic-Depressive Association consensus statement on the use of placebo in clinical trials of mood disorders. (2002) (112)
Glucocorticoid and mineralocorticoid receptor expression in the human hippocampus in major depressive disorder. (2013) (107)
Analysis of miR-137 expression and rs1625579 in dorsolateral prefrontal cortex. (2013) (107)
Use of placebo control groups in evaluating efficacy of treatment of unipolar major depression (2000) (106)
Stress coping stimulates hippocampal neurogenesis in adult monkeys (2010) (105)
Nocturnal sleep apnea/hypopnea is associated with lower memory performance in APOE ε4 carriers (2005) (105)
The effects of a single acute dose of dexamethasone on monoamine and metabolite levels in rat brain. (1985) (104)
From Clinical Research to Clinical Practice: A 4-Year Review of Ziprasidone (2005) (102)
HPA Axis Genetic Variation, Cortisol, and Psychosis in Major Depression (2013) (101)
Current issues in the classification of psychotic major depression. (2007) (101)
Neuropsychological correlates of psychotic features in major depressive disorders: a review and meta-analysis. (2004) (101)
The Genetics of the Mood Disorder Spectrum: Genome-wide Association Analyses of More Than 185,000 Cases and 439,000 Controls (2018) (99)
HPA axis activation in major depression and response to fluoxetine: a pilot study (2004) (98)
Abnormal results of dexamethasone suppression tests in nondepressed patients with diabetes mellitus. (1984) (97)
Antidepressant medications and other treatments of depressive disorders: a CINP Task Force report based on a review of evidence. (2007) (97)
Acute antidepressant effects of intravenous hydrocortisone and CRH in depressed patients: a double-blind, placebo-controlled study. (2000) (96)
Markers in the 15q24 nicotinic receptor subunit gene cluster (CHRNA5‐A3‐B4) predict severity of nicotine addiction and response to smoking cessation therapy (2011) (96)
High-dose spaced theta-burst TMS as a rapid-acting antidepressant in highly refractory depression. (2018) (96)
Nicotine patch and paroxetine for smoking cessation. (2000) (94)
The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) Study: Outcomes from the 2-year and combined maintenance phases. (2007) (92)
Developing novel treatments for mood disorders: accelerating discovery (2002) (92)
A Cognitive–Emotional Biomarker for Predicting Remission with Antidepressant Medications: A Report from the iSPOT-D Trial (2015) (92)
Social stress-related behavior affects hippocampal cell proliferation in mice (2006) (91)
Stanford Neuromodulation Therapy (SNT): A Double-Blind Randomized Controlled Trial. (2021) (90)
Relationships between brain ct scan findings and cortisol in psychotic and nonpsychotic depressed patients (1989) (89)
Mild early life stress enhances prefrontal-dependent response inhibition in monkeys (2005) (89)
Recruiting and retaining future generations of physician scientists in mental health. (2002) (88)
Possible biological mechanisms of the serotonin reuptake inhibitor discontinuation syndrome. Discontinuation Consensus Panel. (1997) (88)
The future of psychiatry as clinical neuroscience. (2009) (85)
ABCB1 (MDR1) polymorphisms and antidepressant response in geriatric depression (2010) (85)
A Prospective Trial of Bupropion SR Augmentation of Partial and Non-Responders to Serotonergic Antidepressants (2003) (85)
Hypomania and mania after withdrawal of tricyclic antidepressants. (1981) (85)
Treatment of chronic depression with sertraline or imipramine: preliminary blinded response rates and high rates of undertreatment in the community. (1995) (84)
The American Psychiatric Publishing textbook of mood disorders (2006) (84)
Onset of major depression during treatment for nicotine dependence. (2003) (83)
Prefrontal Plasticity and Stress Inoculation-Induced Resilience (2009) (83)
Plasma oxytocin concentrations are lower in depressed vs. healthy control women and are independent of cortisol. (2014) (83)
Ketamine: Promising Path or False Prophecy in the Development of Novel Therapeutics for Mood Disorders? (2015) (82)
Extended treatment with bupropion SR for cigarette smoking cessation. (2006) (82)
Toward a biochemical classification of depressive disorders, VII: urinary free cortisol and urinary MHPG in depressions. (1983) (81)
Stress-induced changes in primate prefrontal profiles of gene expression (2007) (80)
Aberrant brain activation during a working memory task in psychotic major depression. (2011) (80)
Rosiglitazone Add-On in Treatment of Depressed Patients with Insulin Resistance: a Pilot Study (2010) (80)
Attenuation of antidepressant and antisuicidal effects of ketamine by opioid receptor antagonism (2019) (80)
Variable telomere length across post-mortem human brain regions and specific reduction in the hippocampus of major depressive disorder (2015) (79)
Essentials of Clinical Psychopharmacology (2001) (79)
Antidepressant discontinuation syndrome: consensus panel recommendations for clinical management and additional research. (2006) (78)
Ketamine: Promising Path or False Prophecy in the Development of Novel Therapeutics for Mood Disorders? (2015) (78)
A word to the wise about ketamine. (2014) (78)
Gene Expression Changes in the Prefrontal Cortex, Anterior Cingulate Cortex and Nucleus Accumbens of Mood Disorders Subjects That Committed Suicide (2012) (77)
Psychosocial outcomes following long-term, double-blind treatment of chronic depression with sertraline vs placebo. (2002) (76)
Dexamethasone increases plasma free dopamine in man. (1984) (75)
Early life stress and novelty seeking behavior in adolescent monkeys (2007) (74)
The Dexamethasone Suppression Test as a Discriminator among Subtypes of Psychotic Patients (1982) (73)
Evidence for alterations of the glial syncytial function in major depressive disorder. (2016) (73)
Experience-dependent asymmetric variation in primate prefrontal morphology (2002) (72)
Extended cognitive behavior therapy for cigarette smoking cessation. (2008) (72)
Aging and the role of the HPA axis and rhythm in sleep and memory-consolidation. (2005) (71)
Toward a biochemical classification of depressive disorders. II. Application of multivariate discriminant function analysis to data on urinary catecholamines and metabolites. (1978) (71)
New approaches to managing psychotic depression. (2003) (69)
Clozapine response and plasma catecholamines and their metabolites (1993) (69)
Anhedonia and general distress show dissociable ventromedial prefrontal cortex connectivity in major depressive disorder (2016) (69)
Early Environmental Regulation of Glucocorticoid Feedback Sensitivity in Young Adult Monkeys (2000) (69)
ABCB1 Genetic Effects on Antidepressant Outcomes: A Report From the iSPOT-D Trial. (2015) (67)
Clinical efficacy of reboxetine in major depression. (2000) (67)
Toward a biochemical classification of depressive disorders, V: Heterogeneity of unipolar depressions. (1982) (67)
Toward a biochemical classification of depressive disorders. X. Urinary catecholamines, their metabolites, and D-type scores in subgroups of depressive disorders. (1989) (66)
Pharmacotherapy of depression and mixed states in bipolar disorder. (2000) (66)
Hippocampal and amygdalar volumes in psychotic and nonpsychotic unipolar depression. (2008) (65)
Diurnal variation of plasma cortisol and homovanillic acid in healthy subjects (1996) (64)
Sertraline versus imipramine to prevent relapse in chronic depression. (2001) (63)
Separation induced changes in squirrel monkey hypothalamic-pituitary-adrenal physiology resemble aspects of hypercortisolism in humans (1999) (63)
The treatment of chronic depression, part 1: study design and rationale for evaluating the comparative efficacy of sertraline and imipramine as acute, crossover, continuation, and maintenance phase therapies. (1998) (62)
Slowing the progression of cognitive decline in alzheimer’s disease using mifepristone (2002) (62)
FMRI activation during executive function predicts response to cognitive behavioral therapy in older, depressed adults. (2015) (62)
Fluoxetine and desipramine in major depressive disorder. (1993) (62)
Psychotic and nonpsychotic depressions: I. comparisons of plasma catecholamines and cortisol measures (1987) (61)
McLean Hospital Depression Research Facility: early-onset phobic disorders and adult-onset major depression (1998) (60)
Cognitive and Noncognitive Symptoms in Dementia Patients: Relationship to Cortisol and Dehydroepiandrosterone (1998) (58)
Postnatal foraging demands alter adrenocortical activity and psychosocial development. (1998) (57)
Serotonin activity in psychotic (delusional) major depression. (1992) (56)
Differential effects of nefazodone and cognitive behavioral analysis system of psychotherapy on insomnia associated with chronic forms of major depression. (2002) (56)
A pilot study of the phase angle between cortisol and melatonin in major depression - a potential biomarker? (2010) (56)
A Word to the Wise About Intranasal Esketamine. (2019) (56)
G protein-linked signaling pathways in bipolar and major depressive disorders (2013) (55)
Stress inoculation modeled in mice (2015) (55)
BDNF and CREB1 genetic variants interact to affect antidepressant treatment outcomes in geriatric depression (2013) (55)
MHPG as a predictor of antidepressant response to imipramine and maprotiline. (1980) (55)
NMDA antagonist treatment of depression (2016) (55)
Early- versus late-onset dythymic disorder: comparison in out-patients with superimposed major depressive episodes. (1999) (54)
Postnatal Experiences and Genetic Effects on Squirrel Monkey Social Affinities and Emotional Distress (1999) (54)
The dexamethasone suppression test in normal control subjects: comparison of two assays and effect of age. (1984) (53)
Glucocorticoid Effects on Mesotelencephalic Dopamine Neurotransmission (1999) (53)
Relating semantic and episodic memory systems. (2002) (53)
Nocturnal sleep apnea/hypopnea is associated with lower memory performance in APOE epsilon4 carriers. (2005) (53)
Inference of cell type content from human brain transcriptomic datasets illuminates the effects of age, manner of death, dissection, and psychiatric diagnosis (2018) (52)
FKBP5 polymorphisms and antidepressant response in geriatric depression (2010) (52)
Effects of major depression diagnosis and cortisol levels on indices of neurocognitive function (2009) (52)
Switching to duloxetine in selective serotonin reuptake inhibitor non- and partial-responders: effects on painful physical symptoms of depression. (2009) (51)
Differences in platelet monoamine oxidase activity in subgroups of schizophrenic and depressive disorders. (1978) (51)
The microRNA network is altered in anterior cingulate cortex of patients with unipolar and bipolar depression. (2016) (50)
Glutamate transporters: a key piece in the glutamate puzzle of major depressive disorder. (2013) (50)
Prevention of recurrent episodes of depression with venlafaxine ER in a 1-year maintenance phase from the PREVENT Study. (2007) (50)
Safety and tolerability of antidepressants: weighing the impact on treatment decisions. (2007) (50)
Addition of atomoxetine for depression incompletely responsive to sertraline: a randomized, double-blind, placebo-controlled study. (2007) (49)
Process irregularity of cortisol and adrenocorticotropin secretion in men with major depressive disorder (2004) (48)
The American Psychiatric Association Publishing Textbook of Psychopharmacology (2017) (48)
Maprotiline treatment in depression. A perspective on seizures. (1986) (48)
Comparison of measures used to determine substance abuse in an inpatient psychiatric population. (1994) (48)
The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) Study: Outcomes from the Acute and Continuation Phases (2007) (48)
Psychobiological Consequences of Social Relationships a (1997) (48)
Effects of short-and long-term administration of tricyclic antidepressants and lithium on norepinephrine turnover in brain. (1976) (47)
Duloxetine for the treatment of major depressive disorder. (2002) (46)
Combined Analysis of Mifepristone for Psychotic Depression: Plasma Levels Associated With Clinical Response (2018) (46)
The mineralocorticoid receptor agonist, fludrocortisone, differentially inhibits pituitary–adrenal activity in humans with psychotic major depression (2013) (46)
Recent Studies on Selective Serotonergic Antidepressants: Trazodone, Fluoxetine, and Fluvoxamine (1987) (46)
Withdrawal symptoms over time among adolescents in a smoking cessation intervention: do symptoms vary by level of nicotine dependence? (2009) (46)
Noradrenergic versus serotonergic antidepressants: predictors of treatment response. (1998) (45)
The acute effects of a mineralocorticoid receptor (MR) agonist on nocturnal hypothalamic–adrenal–pituitary (HPA) axis activity in healthy controls (2007) (45)
Physical symptoms associated with paroxetine withdrawal. (1995) (45)
Glucocorticoid antagonists in neuropsychiatric [corrected] disorders. (2008) (44)
The Roles of Glucocorticoid and Dopaminergic Systems in Delusional (Psychotic) Depression a (1988) (43)
Human amygdala engagement moderated by early life stress exposure is a biobehavioral target for predicting recovery on antidepressants (2016) (43)
Anna-Monika Award Lecture, DGPPN Kongress, 2013: The role of the hypothalamic–pituitary–adrenal (HPA) axis in the pathogenesis of psychotic major depression (2015) (42)
Long-term management of depression. (1994) (42)
Fibroblast growth factor 9 is a novel modulator of negative affect (2015) (42)
Antidepressant effectiveness in severe depression and melancholia. (1999) (42)
Animal models of early life stress: implications for understanding resilience. (2010) (42)
Pramipexole augmentation of a selective serotonin reuptake inhibitor in the treatment of depression. (2000) (41)
Monitoring mental health treatment acceptance and initial treatment adherence in veterans (2010) (40)
Pharmacological principles of antidepressant efficacy (2002) (40)
Efficacy and tolerability of duloxetine, a novel dual reuptake inhibitor, in the treatment of major depressive disorder. (2003) (40)
Mitochondrial Mutations in Subjects with Psychiatric Disorders (2015) (39)
Erratum: Resting-state connectivity biomarkers define neurophysiological subtypes of depression (2017) (39)
Cognitive Correlates of White Matter Growth and Stress Hormones in Female Squirrel Monkey Adults (2004) (38)
Tachyphylaxis after Repeated Antidepressant Drug Exposure in Patients with Recurrent Major Depressive Disorder (2009) (37)
Rapid antidepressant response to alprazolam in depressed patients with high catecholamine output and heterologous desensitization of platelet adenylate cyclase (1988) (37)
Altered choroid plexus gene expression in major depressive disorder (2014) (37)
Phenomenology and treatment of agitation. (1999) (37)
Manual of clinical psychopharmacology, 3rd ed. (1997) (36)
A Delphi-method-based consensus guideline for definition of treatment-resistant depression for clinical trials (2021) (36)
Elevated platelet MAO activity in schizophrenia-related depressive disorders. (1978) (36)
Brain imaging predictors and the international study to predict optimized treatment for depression: study protocol for a randomized controlled trial (2013) (36)
Mitochondrial Complex I Deficiency in Schizophrenia and Bipolar Disorder and Medication Influence (2017) (35)
HPA axis in psychotic major depression and schizophrenia spectrum disorders: Cortisol, clinical symptomatology, and cognition (2019) (35)
The apolipoprotein E ε4 allele and antidepressant efficacy in cognitively intact elderly depressed patients (2003) (35)
Urinary free cortisol levels in anxiety. (1983) (34)
Developing a clinical translational neuroscience taxonomy for anxiety and mood disorder: protocol for the baseline-follow up Research domain criteria Anxiety and Depression (“RAD”) project (2016) (33)
Hypothalamic-pituitary-adrenal axis activity and 1-year outcome in depression (1993) (33)
Toward a biochemical classification of depressive disorders, VI: Platelet MAO activity and clinical symptoms in depressed patients. (1982) (33)
Evidence for Transcriptional Factor Dysregulation in the Dorsal Raphe Nucleus of Patients with Major Depressive Disorder (2012) (33)
Prefrontal networks dynamically related to recovery from major depressive disorder: a longitudinal pharmacological fMRI study (2019) (32)
Depression-free days as a summary measure of the temporal pattern of response and remission in the treatment of major depression: a comparison of venlafaxine, selective serotonin reuptake inhibitors, and placebo. (2003) (32)
Altered brain function underlying verbal memory encoding and retrieval in psychotic major depression (2013) (32)
Decreased Hypothalamic Functional Connectivity with Subgenual Cortex in Psychotic Major Depression (2015) (32)
Personality traits and medical outcome of cardiac illness. (2010) (32)
Open assessment of the safety and efficacy of thioridazine in the treatment of patients with borderline personality disorder. (1989) (32)
Detecting psychotic major depression using psychiatric rating scales. (2006) (31)
An overview of vortioxetine. (2014) (31)
BIOCHEMICAL DISCRIMINATION OF SUBTYPES OF DEPRESSIVE DISORDERS (1979) (30)
ABCB1 (MDR1) predicts remission on P-gp substrates in chronic depression (2014) (29)
Preliminary Evidence That Hippocampal Volumes in Monkeys Predict Stress Levels of Adrenocorticotropic Hormone (2007) (29)
Mifepristone Plasma Level and Glucocorticoid Receptor Antagonism Associated With Response in Patients With Psychotic Depression (2017) (29)
Personalizing antidepressant choice by sex, body mass index, and symptom profile: An iSPOT-D report (2017) (29)
Trazodone in Treatment-resistant Depression: An Open Study (1981) (28)
Erratum: Differential responses to psychotherapy versus pharmacotherapy in patients with chronic forms of major depression and childhood trauma (Proceedings of the National Academy of Sciences of the United States of America (November 25, 2003) 100, 24 (14293-14296)) (2005) (28)
Failure to improve cigarette smoking abstinence with transdermal selegiline + cognitive behavior therapy. (2010) (28)
The DST in psychotic depression: diagnostic and pathophysiologic implications. (1984) (27)
Side Effects to Antidepressant Treatment in Patients With Depression and Comorbid Panic Disorder. (2017) (27)
Expression patterns of corticotropin‐releasing factor, arginine vasopressin, histidine decarboxylase, melanin‐concentrating hormone, and orexin genes in the human hypothalamus (2010) (27)
Major depression among adolescent smokers undergoing treatment for nicotine dependence. (2004) (27)
Antidepressant Outcomes Predicted by Genetic Variation in Corticotropin-Releasing Hormone Binding Protein. (2017) (26)
Trazodone: a 5-year review of antidepressant efficacy. (1987) (26)
Lack of association to a NRG1 missense polymorphism in schizophrenia or bipolar disorder in a Costa Rican population (2011) (25)
Major Depression: Causes or Effects? (2002) (25)
Pretreatment cortisol levels predict posttreatment outcomes among older adults with depression in cognitive behavioral therapy (2013) (25)
Serotonergic synergism: the risks and benefits of combining the selective serotonin reuptake inhibitors with other serotonergic drugs (1998) (25)
WHITHER KETAMINE AS AN ANTIDEPRESSANT: PANACEA OR TOXIN? (2016) (25)
72 MOLECULAR AND CELLULAR MECHANISMS IN DEPRESSION (2002) (24)
Depression secondary to anxiety: findings from the McLean Hospital Depression Research Facility. (1990) (24)
Cognitive and emotional biomarkers of melancholic depression: An iSPOT-D report. (2015) (24)
Platelet monoamine oxidase activity in subgroups of schizophrenic disorders. (1980) (24)
Hypothalamic-pituitary-adrenal axis physiology and cognitive control of behavior in stress inoculated monkeys (2012) (24)
Coping and glucocorticoid receptor regulation by stress inoculation (2014) (23)
Cortisol feedback effects on plasma corticotropin levels in healthy subjects (1997) (23)
The Efficacy of Divalproex Sodium in the Treatment of Agitation Associated With Major Depression (2005) (23)
Baseline cortisol and the efficacy of antiglucocorticoid treatment in mood disorders: A meta-analysis (2019) (23)
Platelet MAO activity and the dexamethasone suppression test in depressed patients. (1983) (23)
Dosing strategies for antidepressant agents. (1991) (23)
The relationship of chronic pain and depression. (2004) (23)
Temporal variability of glucocorticoid receptor activity is functionally important for the therapeutic action of fluoxetine in the hippocampus (2014) (23)
Exon expression in lymphoblastoid cell lines from subjects with schizophrenia before and after glucose deprivation (2009) (23)
Acute and delayed effects of corticotropin-releasing hormone on dopamine activity in man (1994) (23)
Genome-wide association study identifies 30 loci associated with bipolar disorder (2019) (22)
Enhanced signal transduction by adenylate cyclase in platelet membranes of patients showing antidepressant responses to alprazolam: preliminary data. (1985) (22)
Possible nephrotoxic interaction of lithium and metronidazole. (1987) (21)
The unique impact of late-life bereavement and prolonged grief on diurnal cortisol. (2014) (21)
Treatment of severe depression with the selective serotonin reuptake inhibitors (1996) (21)
The acute and post-discontinuation effects of a glucocorticoid receptor (GR) antagonist probe on sleep and the HPA axis in chronic insomnia: a pilot study. (2008) (21)
Hypothalamic–pituitary–adrenal axis effects on plasma homovanillic acid in man (1999) (21)
Career Development Institute with Enhanced Mentoring: A Revisit (2016) (20)
Pharmacological treatments for unipolar depression. (2007) (20)
Bipolar disorder: recent issues in diagnosis and classification. (1998) (20)
In search of moderators and mediators of hyperglycemia with atypical antipsychotic treatment. (2009) (20)
Strain differences in mesotelencephalic dopaminergic neuronal regulation between Fischer 344 and Lewis rats (1999) (20)
Toward a biochemical classification of depressive disorders--VIII. Platelet monoamine oxidase activity in subtypes of depressions. (1985) (19)
Response to Transdermal Selegiline Smoking Cessation Therapy and Markers in the 15q24 Chromosomal Region. (2015) (19)
Dilative cardiomyopathy leading to congestive heart failure in a male squirrel monkey (Saimiri sciureus) (2000) (19)
The Career Development Institute for Psychiatry: An Innovative, Longitudinal Program for Physician-Scientists (2009) (19)
Setting the Record Straight: A Response to Frances Commentary on DSM-V (2009) (19)
Benzodiazepines in the treatment of depressive, borderline personality, and schizophrenic disorders. (1981) (19)
Delusional depression, family history, and DST response: A pilot study (1986) (19)
Fluctuating postdexamethasone cortisol levels in a patient with melancholia. (1982) (19)
Employing pharmacologic treatment of bipolar disorder to greatest effect. (2004) (19)
Application of microarray technology in primate behavioral neuroscience research. (2006) (18)
Effeminacy. I. A quantitative rating scale (1975) (18)
A Randomized Trial of the Efficacy of Group Therapy in Changing Viral Load and CD4 Counts in Individuals Living with HIV Infection (2005) (18)
Anxiety and adjustment disorder: a treatment approach. (1990) (17)
Mesotelencephalic dopamine neurochemical responses to glucocorticoid administration and adrenalectomy in Fischer 344 and Lewis rats (2002) (17)
REVAMP - Research Evaluating the Value of Augmenting Medication with Psychotherapy: rationale and design. (2008) (17)
Toward a Biochemical Classification of Depressive Disorders IX (1985) (17)
Development of New Psychopharmacological Agents for Depression and Anxiety. (2015) (17)
Impaired transactivation of the glucocorticoid receptor cloned from the Guyanese squirrel monkey (2000) (16)
Monoamine oxidase and catechol-o-methyltransferase enzyme activity and gene expression in response to sustained glucocorticoids (2005) (16)
Decisions for the clinician in the treatment of panic disorder: when to treat, which treatment to use, and how long to treat. (1991) (16)
Psychopharmacological screening criteria. APA Committee on Research on Psychiatric Treatments. (1992) (16)
Dexamethasone elevates dopamine in human plasma and rat brain. (1984) (16)
The apolipoprotein E epsilon4 allele and antidepressant efficacy in cognitively intact elderly depressed patients. (2003) (16)
Quantitative Trait Locus and Brain Expression of HLA-DPA1 Offers Evidence of Shared Immune Alterations in Psychiatric Disorders (2016) (15)
Urinary 3-methoxy-4-hydroxyphenylglycol and the depression-type score as predictors of differential responses to antidepressants. (1991) (15)
Premenstrual exacerbation of depression (1995) (15)
Splice-Break: exploiting an RNA-seq splice junction algorithm to discover mitochondrial DNA deletion breakpoints and analyses of psychiatric disorders (2019) (15)
Toward a biochemical classification of depressive disorders IV: Pretreatment urinary MHPG levels as predictors of antidepressant response to imipramine. (1980) (15)
Impairment and distress patterns distinguishing the melancholic depression subtype: an iSPOT-D report. (2015) (15)
Citalopram plus low-dose pipamperone versus citalopram plus placebo in patients with major depressive disorder: an 8-week, double-blind, randomized study on magnitude and timing of clinical response (2011) (14)
Antidepressant early response and remission of venlafaxine and fluoxetine in geriatric outpatients (2000) (14)
Gabapentin and Pregabalin (2009) (14)
Corticotropin-releasing factor 1 receptor haplotype and cognitive features of major depression (2018) (14)
Early maternal availability and prefrontal correlates of reward-related memory (2003) (14)
Cannabis and the Developing Adolescent Brain (2020) (14)
Common treatment problems in depression (1985) (13)
Introduction/Antidepressant Discontinuation Syndrome: An Update on Serotonin Reuptake Inhibitors (1997) (13)
Mutations in squirrel monkey glucocorticoid receptor impair nuclear translocation (2005) (13)
Insular cortex abnormalities in psychotic major depression: Relationship to gender and psychotic symptoms (2013) (13)
The hypothalamic-pituitary-adrenal axis in alcoholics. (1983) (13)
Diagnosis of affective disorders in the elderly. (1984) (13)
Depression and physical symptoms: the mind-body connection. (2004) (13)
Cortisol feedback during the HPA quiescent period in patients with major depression. (2001) (12)
Correction: Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD) (2019) (12)
Connective Tissue Growth Factor Is a Novel Prodepressant (2018) (12)
Social Perspectives on Mood Disorders (2006) (12)
Introduction. Pharmacologic Treatments of Major Depression: Are Two Mechanisms Really Better Than One? (2004) (12)
Issues encountered in recent attempts to develop novel antidepressant agents (2015) (12)
BIOCHEMICAL DISCRIMINATION OF SUBGROUPS OF DEPRESSIVE DISORDERS BASED ON DIFFERENCES IN CATECHOLAMINE METABOLISM (1982) (12)
Treatment of psychotic depression. (1997) (12)
Corrigendum to: Glucocorticoid antagonists in neuropsychiatric disorders [European Journal of Pharmacology 583 (2008) 358–364] (2008) (12)
Dr. Schatzberg Replies (1998) (12)
The role of dopamine in psychotic depression. (1995) (11)
Depression in the elderly. (2002) (11)
Recent Studies on Selective Serotonergic Antidepressants (1987) (11)
Quantitative validation of immunofluorescence and lectin staining using reduced CLARITY acrylamide formulations (2018) (11)
Nonlinear relationship between early life stress exposure and subsequent resilience in monkeys (2019) (11)
Pretreatment urinary MHPG levels as predictors of antidepressant responses to alprazolam. (1985) (11)
Possible pathophysiological mechanisms in subtypes of unipolar depressive disorders based on differences in urinary MHPG levels [proceedings]. (1981) (11)
Catecholamine measures for diagnosis and treatment of patients with depressive disorders. (1980) (11)
Does treatment with antidepressant medication increase suicidal behavior? (1991) (10)
Rigorous Trial Design Is Essential to Understand the Role of Opioid Receptors in Ketamine's Antidepressant Effect. (2019) (10)
Psychotropic dosing and monitoring guidelines (2006) (10)
Speech blockage: a tricyclic side effect. (1978) (10)
Scientific Issues Relevant to Improving the Diagnosis, Risk Assessment, and Treatment of Major Depression. (2019) (10)
Introduction: The Relationship of Chronic Pain and Depression (2004) (9)
Commentary on Abortion Studies of Steinberg and Finer (Social Science & Medicine 2011; 72:72–82) and Coleman (Journal of Psychiatric Research 2009;43:770–6 & Journal of Psychiatric Research 2011;45:1133–4) (2012) (9)
Brain imaging in affective disorders: more questions about causes versus effects. (2002) (9)
Some Comments on Psychedelic Research. (2020) (9)
It Is Time to Take a Stand for Medical Research and Against Terrorism Targeting Medical Scientists (2008) (9)
Overview of anxiety disorders: prevalence, biology, course, and treatment. (1991) (9)
Manual of Clinical Psychopharmacology, Seventh Edition (2010) (9)
Introduction. Reboxetine: a new selective antidepressant for the treatment of depression. (1998) (9)
Coding SNPs included in exon arrays for the study of psychiatric disorders (2008) (9)
Intrinsic reward circuit connectivity profiles underlying symptom and quality of life outcomes following antidepressant medication: a report from the iSPOT-D trial (2020) (9)
Bridging the clinical gap: managing patients with co-occurring mood, anxiety, and alcohol use disorders. Introduction. (2008) (9)
New Paradigm for Treating Recurrent Depression: From Symptom Control to Managing Enduring Vulnerabilities (2006) (8)
Recognition and Treatment of Psychiatric Disorders: A Psychopharmacology Handbook for Primary Care (1999) (8)
Long-term effects of intermittent early life stress on primate prefrontal–subcortical functional connectivity (2021) (8)
The relationships of positive and negative symptoms with neuropsychological functioning and their ability to predict verbal memory in psychotic major depression (2012) (7)
LATE FEEDBACK EFFECTS OF HYPOTHALAMIC–PITUITARY–ADRENAL AXIS HORMONES IN HEALTHY SUBJECTS (1998) (7)
NOREPINEPHRINE OUTPUT AND METABOLISM IN DEPRESSED PATIENTS DURING ANTIDEPRESSANT TREATMENTS (1992) (7)
Diagnosis and Treatment of Psychotic (Delusional) Depression (1994) (7)
Striatal dopamine D2/3 receptor regulation by stress inoculation in squirrel monkeys (2016) (7)
Drs. Schatzberg and Cole Reply (1978) (7)
Identification of potential blood biomarkers associated with suicide in major depressive disorder (2022) (7)
Learning to cope with stress modulates anterior cingulate cortex stargazin expression in monkeys and mice (2016) (6)
Discrimination of facial emotion in depressed patients with visual-perceptual disturbances. (1993) (6)
Stress amplifies sex differences in primate prefrontal profiles of gene expression (2017) (6)
Rapid detection of the C-1496G polymorphism in the CYP2D6 *2 allele. (2001) (6)
86-7 Double-blind crossover antidepressant study: Sertraline vs. imipramine (1997) (6)
Neural cell adhesion molecule peptide mimetics modulate emotionality: pharmacokinetic and behavioral studies in rats and non-human primates (2018) (6)
Clinical use of nefazodone in major depression: a 6-year perspective. (2002) (6)
An Algorithm for the Treatment of Major Depression and its Subtypes (1994) (6)
Inference of Cell Type Composition from Human Brain Transcriptomic Datasets Illuminates the Effects of Age, Manner of Death, Dissection, and Psychiatric Diagnosis (2016) (6)
Valproate in the Treatment of Agitation Associated with Depression (1996) (6)
An empirical data comparison of regulatory agency and malpractice legal problems for psychiatrists. (2014) (6)
Norepinephrine Metabolism in Depressive Disorders: Implications for a Biochemical Classification of Depressions (1978) (6)
Reply: Clinical and Biological Effects of Mifepristone Treatment for Psychotic Treatment (2006) (6)
Dr. Schatzberg and Dr. Rothschild Reply (1993) (5)
22 – Topographic Mapping in Depressed Patients (1986) (5)
Understanding the Clinical Effects and Mechanisms of Action of Neurosteroids. (2020) (5)
Course of Depression in Adults: Treatment Options (1996) (5)
Classification of Depressive Disorders (1978) (5)
Fine-tuning our diagnosis and treatment of depression (2006) (5)
Chapter 30. Psychostimulants in Psychiatry: Amphetamine, Methylphenidate, and Modafinil (2006) (5)
Study guide to psychopharmacology : a companion to the American Psychiatric Publishing textbook of psychopharmacology, fourth edition (2009) (5)
Decoding the temporal nature of brain GR activity in the NFκB signal transition leading to depressive-like behavior (2021) (5)
Effeminacy. II. Variation with social context (1975) (5)
Learning to actively cope with stress in female mice (2018) (5)
Excessive Sleepiness : Determinants , Outcomes , 141 and Context (2008) (5)
Opioids in Psychiatric Disorders: Back to the Future? (2015) (5)
Resilience as a process instead of a trait (2020) (5)
Studies with oral lorazepam in anxiety neurosis associated with depressive symptomatology. (1978) (5)
Achieving Remission and Favorable Outcomes in Patients with Depression/Anxiety and Substance use Disorders (2008) (4)
Restless Legs Syndrome : A Review of Diagnosis and Management (2006) (4)
Ginkgo Biloba and Related Compounds in Alzheimer's Disease (2002) (4)
Using treatment process data to predict maintained smoking abstinence. (2010) (4)
Controversies in antidepressant therapy. (1983) (4)
Empirical comparisons of malpractice claims of different medical specialties (2015) (4)
More Thoughts on Intranasal Esketamine: Response to Drevets et al. (2019) (4)
Mechanisms of Action of Ketamine and Esketamine. (2021) (4)
Chapter 36. Treatment of Childhood and Adolescent Disorders (2006) (4)
Quantitative Trait Locus and Brain Expression of HLA-DPA1 Offers Evidence of Shared Immune Alterations in Psychiatric Disorders. (2016) (4)
Unraveling the opioid actions of S-ketamine and R-ketamine: comment on Bonaventura et al. (2021) (4)
Mirtazapine versus paroxetine in elderly depressed patients (2001) (4)
Understanding the Efficacy and Mechanism of Action of a Dextromethorphan-Bupropion Combination: Where Does It Fit in the NMDA Versus mu-Opioid Story? (2022) (3)
Functional connectivity changes with rapid remission from severe major depressive disorder (2019) (3)
ild Early Life Stress Enhances Prefrontal-Dependent esponse Inhibition in Monkeys (2005) (3)
The use of psychodrama in the hospital setting. (1974) (3)
The chicken and egg of anxiety and depression (2015) (3)
Use of nefazodone in major depression (2002) (3)
Recent Studies of the Biology and Treatment of Depression (2005) (3)
The dynamics of sex: gender differences in psychiatric disorders. (1997) (3)
Empirical evidence of the effect of personality pathology on the outcome of panic disorder. (2018) (3)
Mitochondria DNA copy number, mitochondria DNA total somatic deletions, Complex I activity, synapse number, and synaptic mitochondria number are altered in schizophrenia and bipolar disorder (2022) (3)
Benzodiazepines: therapeutic, biological, and psychosocial issues. (1990) (3)
Variable telomere length across post-mortem human brain regions and specific reduction in the hippocampus of major depressive disorder. (2016) (3)
Biochemical and Neuroendocrine Studies in Psychotic and Nonpsychotic Depressions (1988) (3)
Interpreting Ketamine's Opioid Receptor Dependent Effect: Response to Sanacora. (2019) (3)
Postdexamethasone cortisol levels and subgroups of affective illness. (1985) (3)
90-28 Maintenance therapy of chronic depression: A placebo-controlled trial of sertraline (1997) (3)
Normal HPA Axis and Rhythm, Exemplary Sleep Disorders (2005) (3)
Wilhelm Reich: self-destined victim and social casualty. A study of his trial and appeal. (1972) (3)
A Concise Guide to Understanding Suicide: Anxiety, depression, and suicide: epidemiology, pathophysiology, and prevention (2014) (2)
Constance E. Lieber, Theodore R. Stanley, and the Enduring Impact of Philanthropy on Psychiatry Research (2016) (2)
Augmentation Strategies for Treatment-Resistant Disorders (2015) (2)
Emergency Department Treatment (2015) (2)
Some Thoughts About Governance (2010) (2)
Can Target Engagement Studies Miss Their Targets and Mislead Drug Development? (2021) (2)
Introduction: treating depression and anxiety to remission. (2003) (2)
Cognitive effects of mifepristone in overweight, euthymic adults with depressive disorders. (2018) (2)
Multisensory modulation of body ownership in mice (2020) (2)
Academic Highlights: Transcranial Magnetic Stimulation: Potential New Treatment for Resistant Depression. [CME] (2007) (2)
Psychotic depression -- a newly recognized subtype (1993) (2)
Diagnostic differences in verbal learning strategies and verbal memory in patients with mood disorders and psychotic disorders (2018) (2)
Pharmacologic treatments of major depression: are two mechanisms really better than one? (2004) (2)
Benzodiazepines in depressive disorders: a clinical guide. (1978) (2)
Why isDSM-5Being Delayed? (2010) (2)
The Black Book of Psychotropic Dosing and Monitoring. (2018) (2)
Acute and delayed effects of adrenocorticotropic hormone on dopamine activity in man (1994) (2)
Target Population, Dose, and Timing Considerations for Understanding Naltrexone's Subjective Effect: Response to Amiaz. (2019) (2)
Ineffective military personnel. II. An ethical dilemma for psychiatry. (1974) (2)
Recognizing and Treating the Physical Symptoms of Depression in Primary Care. (2004) (2)
24 Efficacy of Nefazodone in Chronic Depression. (2002) (2)
The journal of psychiatric research celebrates its 50th anniversary in 2011 (2011) (2)
Dr. Kornstein and Colleagues Reply (2001) (2)
Rigorous Translational Models Are Key to Studying Ketamine's Antidepressant Mechanism: Response to Wang and Kaplin. (2019) (1)
Chapter 35. Management of Noncognitive Symptoms of Dementia (2006) (1)
Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT-TRD) induces rapid remission from treatment-resistant depression in a double-blinded, randomized, and controlled trial. (2020) (1)
Genetics in pharmacokinetics? Authors' reply (2004) (1)
An Innovative Approach to Extending the Antidepressant Effects of Intravenous Ketamine in Major Depression. (2022) (1)
C.03.03 Psychiatric and medical comorbidity: Treatment considerations in special patient populations (2004) (1)
Response to the presidential address. (2009) (1)
P.2.a.016 Prevalence and clinical correlates of pain in patients with recurrent major depressive disorder (2007) (1)
Psychoanalytic Contribution to a Theory of Depression (1978) (1)
Non-schizophrenic psychoses: common and distinguishing features. (2004) (1)
Biomarkers and classifications. (2007) (1)
Discussion of "controversies in psychiatry": depression in the medically ill, sleep disorders in the elderly, and the DST. (1985) (1)
P.2.a.018 Interaction of pimpamperone, citalopram and genetic variables in the prediction of antidepressant response (2011) (1)
Glucocorticoids & cognition in depression (2000) (1)
Drs. Murphy and Schatzberg Reply (2004) (1)
Introduction. The Phenomenology and Treatment of Aggression Across Psychiatric Illnesses (1999) (1)
Chapter 34. Treatment of Anxiety Disorders (2006) (1)
Long-term management of depression. Discussion (1994) (1)
Chapter 12. Duloxetine and Milnacipran (2006) (1)
MHPG AS A PREDICTOR OF CLINICAL RESPONSE TO FLUOXETINE (1992) (1)
Recent developments in the acute somatic treatment of major depression. (1992) (1)
Chapter 1. Tricyclic and Tetracyclic Drugs (2006) (1)
General Principles of Psychopharmacological Treatment (2015) (1)
Prevalence, Factor Structure, and Heritability of Avoidant Personality Disorder (2021) (1)
Presidential address. (2010) (1)
Statistics, Placebo Response, and Clinical Trial Design in Psychopharmacology (2009) (1)
Genetic Variation in Corticotropin Releasing Hormone Binding Protein predicts antidepressant outcomes (2018) (1)
Subject Index Vol. 59, 2009 (2009) (1)
Hypomania and Mania After Withdrawal of Tricyclic (1981) (1)
443. Chronic corticosterone on mesocortical dopamine utilization (1996) (1)
Current Prognosis of Depression (2008) (1)
Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT) Induces Functional Connectivity Changes in Emotion Regulation Brain Areas for MDD Patients (2019) (1)
HPA axis activity and cognition in major depression (2000) (0)
Contents, Vol. 20, Supplement 1, 1987 (1987) (0)
Chapter 39. Treatment of Agitation and Aggression in the Elderly (2006) (0)
Chapter 40. Treatment of Personality Disorders (2006) (0)
Psychiatric Foundation Succeeds in Public-Education Mission (2009) (0)
Drs. Rosenbaum and Schatzberg Reply (2006) (0)
SLEEP AND WAKEFULNESS (2007) (0)
DEPRESSION : Mind and Body Advances in the Understanding and Treatment of Depression and its Physical Symptoms Biological and Psychosocial Correlates of Perimenopausal Depression : Implications for Treatment (2007) (0)
Manual of clinical psychopharmacology / Alan F.Schatzberg, Charles DeBattista (2015) (0)
Comment on "Understanding the Clinical Effects and Mechanisms of Action of Neurosteroids": Response to Rubinow et al. (2021) (0)
Third failure for private rocket launch (2008) (0)
Chapter 38. Treatment of Eating Disorders (2006) (0)
Comprar The American Psychiatric Publishing Textbook of Psychopharmacology | Jacob Ballon | 9781585623099 | American Psychiatric Publishing (2009) (0)
Short communication Relating semantic and episodic memory systems (2002) (0)
Antidepressant effectiveness in severe depression and melancholia. Discussion (1999) (0)
Chapter 14. Buspirone (2006) (0)
Chapter 24. Valproate (2006) (0)
Pharmacotherapy for Substance Use Disorders (2015) (0)
Chapter 23. Lithium (2006) (0)
The Effects of Cortisol on Subgenual Cingulate Activity in Depression (2020) (0)
Chapter 42. Treatment During Late Life (2006) (0)
BENZODIAZEPINES IN THE TREATMENT OF DEPRESSIVE, (2006) (0)
Ge of antipsychotics (2002) (0)
Erratum: Mitochondrial involvement in psychiatric disorders (Annals of Medicine (2008) 40 (281-295)) (2011) (0)
DSM-5:The Next Steps Begin (2010) (0)
Methods for treating psychosis associated whose pathogenesis is related to dysfunction via regulating clucocorticoides. (1998) (0)
Continuing to Build a Better APA (2009) (0)
Depression: "Biology, Psychodynamics, And Treatment" (2012) (0)
Some Thoughts About DSM-5 and the Annual Meeting (2010) (0)
Effeminacy Rating Scale (2014) (0)
Diagnosis and Classification (2015) (0)
APA's Institute Looks to Future (2009) (0)
Stress amplifies sex differences in primate prefrontal profiles of gene expression (2017) (0)
P02.201 AD early response and remission of venlafaxine (ven: effexor®) and fluoxetine (flu: prozac®) in geriatric outpatients (2000) (0)
Chapter 22. Drugs to Treat Extrapyramidal Side Effects (2006) (0)
How to Get Congress to Listen (2010) (0)
EFFECTS OF FLUOXETINE AND DESIPRAMINE ON URINARY CATECHOLAMINE AND METABOLITE EXCRETION IN MAJOR DEPRESSION (1992) (0)
Pharmacotherapy in Special Situations (2015) (0)
Researchers have developed a method for using genome sequencing to forecast the risk of a deadly vascular condition (0)
Genetic variation and HPA axis activity: implications for diagnosis and treatment (2012) (0)
Chapter 32. Treatment of Bipolar Disorder (2006) (0)
Chapter 19. Aripiprazole (2006) (0)
Trait Locus Brain HLA-DPA1 Offers Evidence of Shared Immune Alterations in Psychiatric Disorders. (2016) (0)
T162. High-Dose Spaced Theta-Burst Transcranial Magnetic Stimulation as a Rapid-Acting Anti- Depressant in Highly Refractory Depression (2018) (0)
Chapter 29. Sedative-Hypnotics (2006) (0)
Chapter 43. Psychopharmacology During Pregnancy and Lactation (2006) (0)
Stress Coping and Resilience Modeled in Mice (2017) (0)
Board of Trustees Endorses HR 3200 (2009) (0)
Chapter 20. Risperidone (2006) (0)
Chapter 18. Quetiapine (2006) (0)
CNS volume 6 issue 1 Cover and Back matter (2001) (0)
Applying polygenic risk scoring for psychiatric disorders to a large family with bipolar disorder and major depressive disorder (2018) (0)
Chapter 9. Bupropion (2006) (0)
Chapter 26. Gabapentin (2006) (0)
Why APA Supported Health Reform (2010) (0)
Stimulants and Other Fast-Acting Drugs (2015) (0)
Chapter 11. Venlafaxine (2006) (0)
Use of mirtazapine for improving the treatment of people with major depression who are carriers of the gene for apolipoprotein E4. (2002) (0)
Chapter 10. Mirtazapine (2006) (0)
Depression-free days as a flexible measure of response, remission, and elimination of residual symptoms: A pooled analysis of venlafaxine, SSRIs, and placebo (2002) (0)
Comprar Manual of Clinical Psychopharmacology, 6th Edition | Alan F. Schatzberg | 9781585623174 | American Psychiatric Publishing (2007) (0)
Genetic predictors of response to antidepressant (2002) (0)
A-16The Cognitive Profiles of Cushing's Disease and Psychotic Major Depression (2015) (0)
Chapter 21. Ziprasidone (2006) (0)
Brain CT scan findings and HPA axis disruption in psychotic and nonpsychotic depressed patients (1987) (0)
Chapter 16. Clozapine (2006) (0)
Methodes de traitement de la psychose associee a un dysfonctionnement lie aux glucocorticoides (1998) (0)
O19. Attenuation of Anti-Suicidal Effects of Ketamine by Opioid Receptor Antagonism (2019) (0)
Improving Our Annual Meetings (2009) (0)
Introduction (2008) (0)
Exploratory Factor Analysis of the 24-Item Hamilton Depression Rating Scale: (641762010-001) (2010) (0)
Response to Allegations and Call for Open Discussion of Pharmaceutical Funding (2008) (0)
The Black Book of Psychotropic Dosing and Monitoring. (2021) (0)
Chapter 5. Fluvoxamine (2006) (0)
Neurobiologic Foundations of Mood Disorders (2015) (0)
Restoring Pride in Our Profession (2010) (0)
Use of mirtazapine for the treatment of severe depression in a human patient carrying the gene for apolipoprotein E4. (2002) (0)
T13. Functional Impacts of Acute Stress on Negative Affective Circuit Function in Anxiety and Depression (2019) (0)
Chapter 6. Citalopram and S-Citalopram (2006) (0)
Foreword (2006) (0)
Introduction (1997) (0)
Neurotransmission-related gene expression in the frontal pole is altered in subjects with bipolar disorder and schizophrenia (2023) (0)
Hypothalamic-pituitary-adrenal axis physiology and cognitive control of behavior in stress inoculated (2011) (0)
558. Association of CRHR1 TAT Haplotype with Cognitive Features of Major Depressive Disorder (2017) (0)
Methods for the prevention of weight gain as a result of antipsychotics (2002) (0)
Lifetime achievement award lecture: The HPA axis in psychotic depression (2016) (0)
Symposium (1987) (0)
Commentary 6 (2012) (0)
F140. The Effects of Cortisol Administration on Emotion, Stress Reactivity, and Brain Activity in Depression (2019) (0)
Books received (2004) (0)
Annual Conference of the Swiss Society of Sleep Research, Sleep Medicine and Chronobiology (SSSSC) and the Swiss Society of Biological Psychiatry (SSBP). Sleepless Mind. Mindless Sleep? Bern, March 25 and 26, 2009 (2009) (0)
CRH-R1 allelic variation and depressive and psychotic symptoms in major depression (2016) (0)
Chapter 41. Psychiatric Emergencies (2006) (0)
Chapter 44. Treatment of Insomnia (2006) (0)
Chapter 3. Sertraline (2006) (0)
Chapter 27. Lamotrigine (2006) (0)
Ecological validity of social defeat stressors in mouse models of vulnerability and resilience (2023) (0)
Chapter 31 – Psychiatric Disorders (2009) (0)
Abstracts from the 3rd International Forum on Mood and Anxiety Disorders, November 27-30, 2002, Monte-Carlo (2002) (0)
Germany tinkers with university regulations (2008) (0)
EFFECTS OF FLUOXETINE & DESIPRAMINE ON PLATELET IMIPRAMINE BINDING IN MAJOR DEPRESSION (1992) (0)
In Memoriam of George Gardos, MD (2020) (0)
Time to bid goodbye. (2019) (0)
P03-383 - Addition of a Selective 5-HT2A/D4 Antagonist Accelerates the Antidepressant Effects of Citalopram (2010) (0)
Corrigendum to ‘The acute effects of a mineralocorticoid receptor (MR) agonist on nocturnal hypothalamic–adrenal–pituitary (HPA) axis activity in healthy controls’ [Psychoneuroendocrinology (2007) 859–864] (2012) (0)
Some Thoughts on Reorganization (2009) (0)
An Applied Context for Personalized Medicine in Psychiatry (2010) (0)
Self-Assessment in Psychopharmacology (2009) (0)
Chapter 33. Treatment of Schizophrenia (2006) (0)
Trial of Ketamine Masked by Surgical Anesthesia in Depressed Patients (2023) (0)
Rock art carves itself a niche online (2008) (0)
Chapter 31. Treatment of Depression (2006) (0)
Book Forum TEXTBOOKS (2011) (0)
O-48 - the International Study to Predict Optimized Treatment - in Depression: Rational, Design and Initial Findings (2012) (0)
Agomelatine Demonstrates Broad Efficacy in Depression (2007) (0)
Chapter 28 – Psychiatric Disorders (2017) (0)
Erratum to: The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) Study: Outcomes from the Acute and Continuation Phases (2012) (0)
Emerging Approaches in the Treatment of Depression (2015) (0)
reliminary Evidence That Hippocampal Volumes n Monkeys Predict Stress Levels of drenocorticotropic Hormone (2007) (0)
Chapter 7. Monoamine Oxidase Inhibitors (2006) (0)
Chapter 28. Topiramate (2006) (0)
Chapter 37. Treatment of Substance-Related Disorders (2006) (0)
Essentials of Clinical Psychopharmacology, Third Edition (2013) (0)
Some Thoughts onDSM-V (2009) (0)
SYNTHESIS COMMITTEE REPORT (1998) (0)
Large Common Mitochondrial DNA Deletions Are Associated with a Mitochondrial SNP T14798C Near the 3′ Breakpoints (2022) (0)
Good Fiscal News for APA (2010) (0)
Contents Vol. 59, 2009 (2009) (0)
Meeting Highlights a Field With Much to Celebrate (2010) (0)
Chapter 8. Trazodone and Nefazodone (2006) (0)
Introduction: Recent Developments in Achieving Depression Remission (2003) (0)
As APA Is at Major Crossroads, Your Vote Carries Special Weight (2009) (0)
P.2.a.015 Addition of atomoxetine for depression incompletely responsive to sertraline: a randomized, double-blind, placebo-controlled study (2006) (0)
subtypes of psychotic patients. The dexamethasone suppression test as a discriminator among (2013) (0)
The role of dopamine in psychotic depression. Discussion (1995) (0)
The silver lining of recent effectiveness trials (2009) (0)
Biological discrimination between anxiety and depression (1990) (0)
Chapter 17. Olanzapine (2006) (0)
Some Thoughts on Recent Events (2009) (0)
Chapter 2. Fluoxetine (2006) (0)
Antidepressant interventions in the HPA system (2008) (0)
Explorations in Psychohistory: The Wellfleet Papers (1976) (0)
Chapter 25. Carbamazepine and Oxcarbazepine (2006) (0)
Chapter 4. Paroxetine (2006) (0)
Theoretical basis for response to steroid suppression in major depression. (1992) (0)
Post-mortem molecular profiling of three psychiatric disorders (2017) (0)
BENZODIAZEPINES INTHETREATMENTOFDEPRESSIVE, BORDERLINE PERSONALITY, ANDSCHIZOPHRENIC DISORDERS (1981) (0)
FGF-2 related methods for the diagnosis and treatment of depression (2006) (0)
Reply to Letter to the Editor “Should We Keep Calling Antidepressants Antidepressants?” (2001) (0)
Nonlinear relationship between early life stress exposure and subsequent resilience in monkeys (2019) (0)
Chapter 15. Classic Antipsychotic Medications (2006) (0)
Recent research on pharmacogenetics in geriatric depression and mifepristone in delusional depression (2001) (0)
Chapter 13. Benzodiazepines (2006) (0)
Publishing & Business Staff (2015) (0)
Symposium: Elizabeth young memorial symposium – stress, depression and the HPA-axis Time: Friday, 07/Sep/2018: 4:00pm–6:00pm (2019) (0)
We've Lost a Champion (2009) (0)
Don't Pass Up This APA Gem! (2009) (0)
mtDNA copy number, mtDNA total somatic deletions, Complex I activity, synapse number and synaptic mitochondria number are altered in schizophrenia and bipolar disorder (2022) (0)

This paper list is powered by the following services:

Other Resources About Alan Schatzberg

en.wikipedia.org

What Schools Are Affiliated With Alan Schatzberg?

Alan Schatzberg is affiliated with the following schools:

Stanford University